Format

Send to

Choose Destination
Cancer. 2015 Jul 1;121(13):2108-20. doi: 10.1002/cncr.29321. Epub 2015 Mar 27.

Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer.

Author information

1
Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
2
Northern California Gynecologic Cancer Program, Kaiser Permanente San Francisco, San Francisco, California.
3
Gynecology/Oncology Division, University of California San Francisco/Mt. Zion Cancer Center, San Francisco, California.
4
Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.
5
Division of Gynecologic Oncology, University of North Carolina, Chapel Hill, North Carolina.
6
Norton Cancer Institute, Louisville, Kentucky.
7
Helen F. Graham Cancer Center, Christiana Care Health System, Newark, Delaware.
8
Cancer Center, Billings Clinic, Billings, Montana.

Abstract

Mortality from ovarian cancer may be dramatically reduced with the implementation of attainable prevention strategies. The new understanding of the cells of origin and the molecular etiology of ovarian cancer warrants a strong recommendation to the public and health care providers. This document discusses potential prevention strategies, which include 1) oral contraceptive use, 2) tubal sterilization, 3) risk-reducing salpingo-oophorectomy in women at high hereditary risk of breast and ovarian cancer, 4) genetic counseling and testing for women with ovarian cancer and other high-risk families, and 5) salpingectomy after childbearing is complete (at the time of elective pelvic surgeries, at the time of hysterectomy, and as an alternative to tubal ligation). The Society of Gynecologic Oncology has determined that recent scientific breakthroughs warrant a new summary of the progress toward the prevention of ovarian cancer. This review is intended to emphasize the importance of the fallopian tubes as a potential source of high-grade serous cancer in women with and without known genetic mutations in addition to the use of oral contraceptive pills to reduce the risk of ovarian cancer.

KEYWORDS:

BRCA; Cascade genetic testing; carriers; fallopian tube; genetic testing; mastectomy; oral contraceptives; ovarian cancer; prevention; risk-reducing bilateral salpingo-oophorectomy (BSO); salpingectomy

PMID:
25820366
DOI:
10.1002/cncr.29321
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center